These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 32155996)

  • 1. Acetylcholinesterase: The "Hub" for Neurodegenerative Diseases and Chemical Weapons Convention.
    Cavalcante SFA; Simas ABC; Barcellos MC; de Oliveira VGM; Sousa RB; Cabral PAM; Kuča K; França TCC
    Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32155996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review on coumarins as acetylcholinesterase inhibitors for Alzheimer's disease.
    Anand P; Singh B; Singh N
    Bioorg Med Chem; 2012 Feb; 20(3):1175-80. PubMed ID: 22257528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Are Irreversible Inhibitors the Future?
    Moss DE
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32414155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs.
    Lazarevic-Pasti T; Leskovac A; Momic T; Petrovic S; Vasic V
    Curr Med Chem; 2017; 24(30):3283-3309. PubMed ID: 28685687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of molecular descriptors for design of novel Isoalloxazine derivatives as potential Acetylcholinesterase inhibitors against Alzheimer's disease.
    Gurung AB; Aguan K; Mitra S; Bhattacharjee A
    J Biomol Struct Dyn; 2017 Jun; 35(8):1729-1742. PubMed ID: 27410776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4,6-Diphenylpyrimidine Derivatives as Dual Inhibitors of Monoamine Oxidase and Acetylcholinesterase for the Treatment of Alzheimer's Disease.
    Kumar B; Dwivedi AR; Sarkar B; Gupta SK; Krishnamurthy S; Mantha AK; Parkash J; Kumar V
    ACS Chem Neurosci; 2019 Jan; 10(1):252-265. PubMed ID: 30296051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Alzheimer disease. Pseudo-irreversible AChE inhibition with rivastigmine].
    Med Monatsschr Pharm; 1998 Aug; 21(8):248-9. PubMed ID: 9758554
    [No Abstract]   [Full Text] [Related]  

  • 8. Acetylcholinesterase and its inhibition in Alzheimer disease.
    Lane RM; Kivipelto M; Greig NH
    Clin Neuropharmacol; 2004; 27(3):141-9. PubMed ID: 15190239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection.
    Singh M; Kaur M; Kukreja H; Chugh R; Silakari O; Singh D
    Eur J Med Chem; 2013; 70():165-88. PubMed ID: 24148993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in behavioral and psychological symptoms of dementia by rivastigmine patch in a group of Italian elderly patients with Alzheimer's disease.
    Servello A; Ettorre E; Cacciafesta M
    Panminerva Med; 2017 Sep; 59(3):275-277. PubMed ID: 28665099
    [No Abstract]   [Full Text] [Related]  

  • 11. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, biological evaluation, and docking study of 4-isochromanone hybrids bearing N-benzyl pyridinium moiety as dual binding site acetylcholinesterase inhibitors (part II).
    Wang J; Wang C; Wu Z; Li X; Xu S; Liu J; Lan Q; Zhu Z; Xu J
    Chem Biol Drug Des; 2018 Mar; 91(3):756-762. PubMed ID: 29112799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
    Pacheco G; Palacios-Esquivel R; Moss DE
    J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
    Ballard CG
    Eur Neurol; 2002; 47(1):64-70. PubMed ID: 11803198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracts from Traditional Chinese Medicinal Plants Inhibit Acetylcholinesterase, a Known Alzheimer's Disease Target.
    Kaufmann D; Kaur Dogra A; Tahrani A; Herrmann F; Wink M
    Molecules; 2016 Aug; 21(9):. PubMed ID: 27589716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer's disease: a retrospective survival analysis.
    Mueller C; Perera G; Hayes RD; Shetty H; Stewart R
    Age Ageing; 2018 Jan; 47(1):88-94. PubMed ID: 28655175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).
    McHardy SF; Wang HL; McCowen SV; Valdez MC
    Expert Opin Ther Pat; 2017 Apr; 27(4):455-476. PubMed ID: 27967267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, biological evaluation, and molecular modeling of coumarin-piperazine derivatives as acetylcholinesterase inhibitors.
    Modh RP; Kumar SP; Jasrai YT; Chikhalia KH
    Arch Pharm (Weinheim); 2013 Nov; 346(11):793-804. PubMed ID: 24591157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A molecular approach in drug development for Alzheimer's disease.
    Agatonovic-Kustrin S; Kettle C; Morton DW
    Biomed Pharmacother; 2018 Oct; 106():553-565. PubMed ID: 29990843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of high-affinity phenyltetrahydroisoquinoline aldoximes, linked through anti-triazoles, as reactivators of phosphylated cholinesterases.
    Maček Hrvat N; Kalisiak J; Šinko G; Radić Z; Sharpless KB; Taylor P; Kovarik Z
    Toxicol Lett; 2020 Mar; 321():83-89. PubMed ID: 31863869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.